A Phase I study of expanded and activated allogeneic gamma-delta T cells for patients with blood cancers following haploidentical stem cell transplantation.
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Allogeneic-gamma-delta-T-cell-therapy (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 21 Sep 2017 New trial record
- 19 Sep 2017 According to an Incysus media release, company has submitted Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate this study.